This site is intended for health professionals only

Home / News / Muscle relaxants ‘largely ineffective’ for low back pain, study finds

Muscle relaxants ‘largely ineffective’ for low back pain, study finds

By Allie Anderson
Freelance journalist

07 Jul 2021

Treating low back pain with commonly prescribed muscle relaxants is ‘largely ineffective’, according to a new study.

Researchers in Australia conducted a review of literature published up to February 2021 to examine the efficacy, acceptability and safety of a number of different muscle relaxants. The findings have been published today (7 July) in the BMJ.

Evidence from 31 randomised controlled trials involving more than 6,500 participants with non-specific low back pain suggested that while the drugs may successfully treat short-term pain, the effect is ‘too small to be considered clinically meaningful’.

However, the certainty of evidence overall is low and larger trials must be conducted to establish more robust clinical recommendations, the researchers said.

The study looked at the effects on acute, chronic and mixed low back pain of the following, widely used muscle relaxants:

  • non-benzodiazepine antispasmodics (carisoprodol, cyclobenzaprine, metaxalone, methocarbamol, thiocolchicoside, tizanidine, tolperisone, orphenadrine)
  • antispastics (baclofen, dantrolene)
  • benzodiazepines (diazepam)
  • miscellaneous muscle relaxants (botulinum toxin, eszopiclone).

Researchers compared the effectiveness of the drugs with placebo, usual care and no treatment in adults with non-specific low back pain. The outcomes examined were pain intensity and satisfaction with the treatment, disability, adverse events, serious adverse events, and tolerability.

They found that muscle relaxants might reduce pain intensity at two weeks or less for patients with acute low back pain, compared with controls, but that the effect is minimal and not clinically meaningful.

There was little to no effect on pain intensity at three to 13 weeks, or on disability at all follow-up time points.

Moreover, the medications might induce side effects including dizziness, drowsiness, headache and nausea, and have little to no effect on treatment discontinuation compared with controls.

The authors said that although the pain-relieving effects were modest, they ‘could still mean that some, but not all, individuals gain a worthwhile benefit’.

‘We would encourage clinicians to discuss this uncertainty in the efficacy and safety of muscle relaxants with patients, sharing information about the possibility for a worthwhile benefit in pain reduction but increased risk of experiencing a non-serious adverse event, to allow them to make informed treatment decisions,’ they said.

‘Large, high-quality, placebo-controlled trials are urgently needed to resolve uncertainties about the efficacy and safety of muscle relaxants for low back pain.’

Want news like this straight to your inbox?

Latest News

Covid booster jab: Over-40s invited to book after three months
People aged over 40 and in high-risk groups are being invited to book their Covid...
NHS England to launch campaign to increase ‘attractiveness’ of pharmacy career
NHS England and Improvement is looking for suppliers to create a recruitment campaign to encourage...
Community pharmacy
Automated pharmacy services may be jeopardizing patient safety, says PDA
Community pharmacists are increasingly concerned about the use of automation within pharmacy and its impact on patient safety, the...